These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 35126667)

  • 1. Systematic review and meta-analysis: evaluating response to empiric anti-TNF dose intensification for secondary loss of response in Crohn's disease.
    Srinivasan A; Gilmore R; van Langenberg D; De Cruz P
    Therap Adv Gastroenterol; 2022; 15():17562848211070940. PubMed ID: 35126667
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Systematic review with meta-analysis: loss of response and requirement of anti-TNFα dose intensification in Crohn's disease.
    Qiu Y; Chen BL; Mao R; Zhang SH; He Y; Zeng ZR; Ben-Horin S; Chen MH
    J Gastroenterol; 2017 May; 52(5):535-554. PubMed ID: 28275925
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anti-TNF Re-induction Is as Effective, Simpler, and Cheaper Compared With Dose Interval Shortening for Secondary Loss of Response in Crohn's Disease.
    Srinivasan A; Vasudevan A; McFarlane A; Sparrow MP; Gibson PR; Van Langenberg DR
    J Crohns Colitis; 2018 Feb; 12(3):280-288. PubMed ID: 29077839
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dose intensification strategy influences infliximab pharmacokinetics but not clinical response after the same number of doses.
    Srinivasan A; De Cruz P; Sam M; Toong C; van Langenberg DR
    J Gastroenterol Hepatol; 2023 May; 38(5):724-732. PubMed ID: 36692034
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Outcome after a dose "de-intensification" strategy with anti-TNF drugs in patients with Crohn's disease.
    Chaparro M; Barreiro-de Acosta M; García-Planella E; Domènech E; Bermejo F; Calvet X; Martín Arranz MD; Monfort D; Gisbert JP
    Gastroenterol Hepatol; 2016 Apr; 39(4):255-60. PubMed ID: 26620278
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tumor necrosis factor-alpha antibody for maintenance of remission in Crohn's disease.
    Behm BW; Bickston SJ
    Cochrane Database Syst Rev; 2008 Jan; (1):CD006893. PubMed ID: 18254120
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Predictors of response to Infliximab in children with luminal Crohn's disease.
    Grover Z; Biron R; Carman N; Lewindon P
    J Crohns Colitis; 2014 Aug; 8(8):739-46. PubMed ID: 24445015
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adalimumab Drug Levels at Secondary Loss of Response Do Not Predict Response to Dose-intensification in Crohn's Disease: A Retrospective, International Multicenter Study.
    Little RD; Swaine A; Reynolds R; Gibson DJ; Barrau M; D'Errico F; Hampal R; Sparrow MP; Roblin X; Irving PM; Ward MG
    Inflamm Bowel Dis; 2023 Nov; ():. PubMed ID: 37951220
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy of a concomitant elemental diet to reduce the loss of response to adalimumab in patients with intractable Crohn's disease.
    Sugita N; Watanabe K; Kamata N; Yukawa T; Otani K; Hosomi S; Nagami Y; Tanaka F; Taira K; Yamagami H; Tanigawa T; Shiba M; Watanabe T; Tominaga K; Kabata D; Shintani A; Arakawa T; Fujiwara Y
    J Gastroenterol Hepatol; 2018 Mar; 33(3):631-637. PubMed ID: 28857255
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Systematic review: efficacy of escalated maintenance anti-tumour necrosis factor therapy in Crohn's disease.
    Mattoo VY; Basnayake C; Connell WR; Ding N; Kamm MA; Lust M; Niewiadomski O; Thompson A; Wright EK
    Aliment Pharmacol Ther; 2021 Aug; 54(3):249-266. PubMed ID: 34153124
    [TBL] [Abstract][Full Text] [Related]  

  • 11. C-Reactive protein reduction rate following initiation of anti-tumor necrosis factor α induction therapy predicts secondary loss of response in patients with Crohn's disease.
    Song JH; Hong SN; Lee JE; Kim K; Kim TJ; Kim ER; Chang DK; Kim YH
    Scand J Gastroenterol; 2019 Jul; 54(7):876-885. PubMed ID: 31303093
    [No Abstract]   [Full Text] [Related]  

  • 12. Frequency and Effectiveness of Empirical Anti-TNF Dose Intensification in Inflammatory Bowel Disease: Systematic Review with Meta-Analysis.
    Guberna L; Nyssen OP; Chaparro M; Gisbert JP
    J Clin Med; 2021 May; 10(10):. PubMed ID: 34069295
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical and Immunological Factors Associated with Recommended Trough Levels of Adalimumab and Infliximab in Patients with Crohn's Disease.
    Orts B; Gutierrez A; Madero L; Sempere L; Frances R; Zapater P
    Front Pharmacol; 2021; 12():795272. PubMed ID: 35046819
    [No Abstract]   [Full Text] [Related]  

  • 14. Long-term clinical and real-world experience with Crohn's disease treated with anti-tumor necrosis factor-α antibodies.
    Otake H; Matsumoto S; Mashima H
    Intest Res; 2022 Oct; 20(4):464-474. PubMed ID: 35350094
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Colonoscopy-guided therapy for the prevention of post-operative recurrence of Crohn's disease.
    Candia R; Bravo-Soto GA; Monrroy H; Hernandez C; Nguyen GC
    Cochrane Database Syst Rev; 2020 Aug; 8(8):CD012328. PubMed ID: 32746500
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Primary Non-Response to Tumor Necrosis Factor Antagonists is Associated with Inferior Response to Second-line Biologics in Patients with Inflammatory Bowel Diseases: A Systematic Review and Meta-analysis.
    Singh S; George J; Boland BS; Vande Casteele N; Sandborn WJ
    J Crohns Colitis; 2018 May; 12(6):635-643. PubMed ID: 29370397
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A virtual clinic increases anti-TNF dose intensification success via a treat-to-target approach compared with standard outpatient care in Crohn's disease.
    Srinivasan A; van Langenberg DR; Little RD; Sparrow MP; De Cruz P; Ward MG
    Aliment Pharmacol Ther; 2020 Jun; 51(12):1342-1352. PubMed ID: 32379358
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Loss of response and need for adalimumab dose intensification in Crohn's disease: a systematic review.
    Billioud V; Sandborn WJ; Peyrin-Biroulet L
    Am J Gastroenterol; 2011 Apr; 106(4):674-84. PubMed ID: 21407178
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Smoking May Reduce the Effectiveness of Anti-TNF Therapies to Induce Clinical Response and Remission in Crohn's Disease: A Systematic Review and Meta-analysis.
    Lee S; Kuenzig ME; Ricciuto A; Zhang Z; Shim HH; Panaccione R; Kaplan GG; Seow CH
    J Crohns Colitis; 2021 Jan; 15(1):74-87. PubMed ID: 32621742
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Azathioprine discontinuation earlier than 6 months in Crohn's disease patients started on anti-TNF therapy is associated with loss of response and the need for anti-TNF dose escalation.
    Viazis N; Koukouratos T; Anastasiou J; Giakoumis M; Triantos C; Tsolias C; Theocharis G; Karamanolis DG
    Eur J Gastroenterol Hepatol; 2015 Apr; 27(4):436-41. PubMed ID: 25874518
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.